NASDAQ:AKTS Aktis Oncology Q1 2026 Earnings Report $31.15 +2.45 (+8.54%) Closing price 06/25/2026 04:00 PM EasternExtended Trading$32.13 +0.98 (+3.13%) As of 07:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Aktis Oncology EPS ResultsActual EPS-$0.38Consensus EPS -$0.37Beat/MissMissed by -$0.01One Year Ago EPSN/AAktis Oncology Revenue ResultsActual Revenue$3.23 millionExpected Revenue$2.23 millionBeat/MissBeat by +$997.00 thousandYoY Revenue GrowthN/AAktis Oncology Announcement DetailsQuarterQ1 2026Date5/11/2026TimeBefore Market OpensConference Call DateMonday, May 11, 2026Conference Call Time4:00PM ETUpcoming EarningsAktis Oncology's Q2 2026 earnings is estimated for Monday, August 10, 2026, based on past reporting schedules, with a conference call scheduled on Tuesday, August 11, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Aktis Oncology Earnings HeadlinesAktis Oncology (NASDAQ:AKTS) Receives $34.00 Average PT from AnalystsJune 24 at 5:23 AM | americanbankingnews.comAktis is a Strong Buy at Raymond James on therapeutic platformJune 16, 2026 | seekingalpha.com2,000 missiles didn't hit Iran. They hit China.Iran sold 90% of its oil to China. Venezuela secretly shipped 80% of its exports to the same buyer. Within 60 days, America cut both supply lines - starving China's AI power grid of the cheap, endless fuel it needs to compete. Now all that energy flows through a single American chokepoint: one company, 140,000 miles of steel, and no competition. Dylan Jovine has identified the stock at the center of this strategy, along with three ascending price targets.June 26 at 1:00 AM | Behind the Markets (Ad)This Aktis Oncology Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For TuesdayJune 16, 2026 | benzinga.comAktis Oncology, Inc. (AKTS) Presents at Jefferies Global Healthcare Conference 2026 - SlideshowJune 12, 2026 | seekingalpha.comAktis Oncology: Mini-Proteins With A Targeted PunchJune 11, 2026 | seekingalpha.comSee More Aktis Oncology Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Aktis Oncology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aktis Oncology and other key companies, straight to your email. Email Address About Aktis OncologyAktis Oncology (NASDAQ:AKTS) (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments. The company's activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones. Aktis engages in translational research to move promising molecules from discovery into human testing, and may pursue collaborations or other corporate-development strategies common in the biopharmaceutical sector to accelerate program advancement and broaden development capabilities. As a publicly traded company on the Nasdaq, Aktis Oncology operates within the broader biotech and pharmaceutical ecosystem and reports progress on its programs to investors and other stakeholders. Public disclosures and regulatory filings are the primary sources for up-to-date information on the company’s pipeline, development timelines and corporate plans. I couldn't find sufficiently detailed, independently verifiable public information on specific products, leadership or geographic headquarters to include here without risking inaccuracy. View Aktis Oncology ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Micron’s HBM Surge Could Redefine the AI Growth StoryCarnival's Second Quarter: Is the Stock Still Complicated?Paychex Stock Looks Beaten Down, But Not BrokenWhy KB Home Could Reward Patient Investors LaterWashington’s Quantum Push Puts IBM and IonQ on the ThroneFedEx’s Earnings Drop May Be Missing the Bigger Freight Story2 Space and Defense Stocks Turning Backlogs Into Revenue Growth Upcoming Earnings NIKE (6/30/2026)PepsiCo (7/9/2026)Delta Air Lines (7/9/2026)Fastenal (7/13/2026)Bank of America (7/14/2026)The Goldman Sachs Group (7/14/2026)JPMorgan Chase & Co. (7/14/2026)Wells Fargo & Company (7/14/2026)Citigroup (7/14/2026)ASML (7/15/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
